COVID-19 Update

We have now joined the COVID-19 Pharmacology Resource Center. Conquering COVID-19 with clinical pharmacology, innovation, and collaboration.

More information available at the Covid-19 Pharmacology Resource web page

Pharmetheus is currently working with a number of clients to address the impact of the current COVID-19 epidemic to their ongoing clinical drug development programs. We would like to share our high level approach with the community at large. We see the current situation as both a challenge to our industry/sector but also an opportunity for appropriate and quantitative approaches to mitigate upon these challenges. We believe there are "fit for purpose" options for a broad range of plausible scenarios in clinical trial conduct that have emerged or could emerge.

See our approach

We are very happy to welcome two new team members, Julie Janssen, MIDD consultant, and Anna Pousette, Contracts Manager. Julie's research experience includes the application of pharmacometrics in the clinical setting, chemotherapy and targeted therapies, as well as special patient populations (e.g. pediatrics and pregnancy). Julie is based in the Netherlands. See Julie's bio here. Anna has long experience of project coordination and procurement. Anna will work from our Uppsala office in Sweden. See Anna's bio here.

Going to WCoP 2020 in Cape Town?

Join the 1-day hands-on workshop "Open source PBPK modelling with the OSPSuite (PK-Sim® & MoBi®) for MIDD" hosted by Pharmetheus and Pharmacometrics Africa.

Read more and register here.
Register soon, only limited seats available!

It is with great pleasure that we welcome Siv Jönsson to our team! Siv has been working in the pharmacokinetic, pharmacodynamic and pharmacometric areas in the pharmaceutical industry for a total of 5 years (Kabi Pharmacia, AstraZeneca), as a regulatory assessor at the Swedish Medical Products Agency for 9 years, and spent +10 years in academia as a senior lecturer and researcher dealing with methodological and applied pharmacometric projects. See her bio here.

Mechanism based pharmacometric analysis can be a powerful tool in the development of biosimilar drugs. Pharmetheus recently supported a client with evaluating the impact of study design and expected product differences on the power to demonstrate PK and PD similarity. Find out more in a recent paper by Ari Brekkan et al. AAPS J. 2019 Jul 8;21(5):85.

We are glad to announce that Ida Netterberg (MIDD consultant) is returning to Pharmetheus after recently defending her PhD thesis at Uppsala University. Ida’s thesis focused on pharmacometric evaluation of biomarkers to improve treatment in oncology. See Ida's bio here.

We are happy to welcome Ola Caster in our growing enabler team. Ola comes most recently from a position as a Senior Researcher at the Uppsala Monitoring Centre, where he worked primarily with methods for adverse effect detection and benefit-risk assessment in the post-marketing setting. He has more than ten years of experience from research in statistics and data science, including a PhD in Computer and Systems Sciences. See Ola's bio here.

The Pharmetheus team has recently been strengthened by our first dedicated Project Coordinator, Marie Karlsson. Marie has long prior experience in monitoring data processing and project management in software development. See Marie's bio here. Welcome!